Reimbursement

Download Early stage dialogue: Operating reimbursement in parallel with accelerated regulatory approval

Download Early stage dialogue: Operating reimbursement in parallel with accelerated regulatory approval > The 9th World Stem Cells & Regenerative Medicine Congress is Europe’s leading scientific and business development event for the stem cell and cell therapy industry. At the 2013 event, delegates were fortunate enough to hear from Gil Van Bokkelen & Michael Werner who delivered the presentation ‘Early stage …

How long will markets sustain high priced orphan drugs?

The orphan drug market was worth more than $50 billion in 2011 and turns out blockbusters at the same rate as the broader industry, according to a recent Thomson Reuters analysis. This is mostly due to the high-prices of therapies developed by the industry for rare disease patients. Even though the segment has just started to provide a great source …

Europe’s reaction to CAVOMP’s harmonization in the orphan drugs space

There are conflicting opinions about CAVOMP and how far it will go with harmonizing reimbursement policies among the 27 countries in the EU. We need to remember that sovereignty issues to consider as well. Governments, the EMA, industry, payers and patients, all feel that more collaboration is necessary in order to align everyone's interests. It may also be necessary to …